supported by the National Natural Science Foundation of China (82203804,81872159);345 Talent Project of Shengjing Hospital of China Medical University。
CDK4/6 inhibitors are routinely recommended agents for the treatment of advanced HR+HER2-breast cancer.However,their therapeutic effectiveness in triple-negative breast cancer(TNBC)remains controversial.Here,we observ...